Summary of demographics of patients included in the MaCROS study
| Patient number | Sex (male=M/female=F) | Diagnosis | Cycle/day | Consent | Paper/diary | Stopped further participation in MaCROS study |
| 1 | F | Ewing’s sarcoma | Last cycle | 10/06/2019 | Paper | Stopped participation |
| 2 | F | Osteosarcoma | Cycle 6 | 02/07/2019 | Web app | |
| 3 | F | Undifferentiated sarcoma | Cycle 2 | 02/07/2019 | Not completed | |
| 4 | F | HR NBL HD chemotherapy and stem cell rescue | Day 0 | 04/07/2019 | Not completed | |
| 5 | M | HR NBL | Day 20 | 04/07/2019 | Paper | |
| 6 | F | HR NBL- HD chemotherapy and stem cell rescue | Day 0 | 04/07/2019 | Web app | |
| 7 | M | AML | Cycle 1 | 04/09/2019 | Web app | |
| 8 | M | NHL | Cycle 2 | 05/09/2019 | Paper | |
| 9 | M | Metastatic-relapsed osteosarcoma | Cycle 1 | 09/07/2019 | Paper | Stopped participation |
| 10 | M | Osteosarcoma | Cycle 3 | 19/11/2019 | Paper |
AML, acute myeloid leukaemia; HD, high dose; HR NBL, high-risk neuroblastoma; NHL, non-Hodgkins lymphoma.